NSE: DRREDDY · 13 October 2026
- Dr. Reddy's Laboratories (DRREDDY) shares advanced by 2.71% today, trading near the higher end of the day's session between ₹1,224.40 and ₹1,234.60 after opening at ₹1,231.10.
- The United States Food and Drug Administration completed a pre-approval inspection at the company's FTO-11 manufacturing facility located in Pydibhimavaram, Andhra Pradesh, between October 5 and October 7, 2026. The inspection concluded with the issuance of a Form 483 containing two observations, which the company stated it will address within the stipulated timeline.
- Trading volume was 0.05 times the 20-day average daily volume.
Why is Dr. Reddy S Laboratories share price rising on 13 October 2026?
Dr. Reddy's Laboratories (DRREDDY) shares advanced by 2.71% today, trading near the higher end of the day's session between ₹1,224.40 and ₹1,234.60 after opening at ₹1,231.10.
The broader market showed positive momentum as the Nifty benchmark rose 0.56%, while the Nifty Pharma sector index declined by 0.45%, highlighting a stock-specific outperformance by Dr. Reddy's relative to its sectoral peers. Over a broader timeframe, the stock has posted gains of 2.19% over the past 5 trading days and 7.56% over the past 20 trading days.
In recent company updates, Dr. Reddy's announced that the USFDA completed a pre-approval inspection at its FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh, issuing a Form 483 with two observations. Additionally, the company has scheduled its Q2FY27 financial results announcement and earnings call for October 23, 2026, alongside ongoing preparations for its exclusive distribution partnership for the Qdenga dengue vaccine.
1.13 lakh shares traded by 13 October 2026 · 09:35 AM IST. This compares with a 20-day average daily volume of 23.35 lakh shares (0.05 times). The five-day average daily volume was 20.52 lakh shares. Separately, the NSE report for 12 October 2026 showed 8.05 lakh shares delivered, representing 45.84% of that day’s traded volume. The same report recorded 62,826 trades.
The move appears largely stock-specific and consistent with recent positive price momentum over the past 20 trading days, outperforming the broader pharmaceutical sector despite volume running near recent averages.
Latest Company Developments
The United States Food and Drug Administration completed a pre-approval inspection at the company's FTO-11 manufacturing facility located in Pydibhimavaram, Andhra Pradesh, between October 5 and October 7, 2026. The inspection concluded with the issuance of a Form 483 containing two observations, which the company stated it will address within the stipulated timeline.
Regulatory inspections and observations at key manufacturing sites are vital for maintaining compliance and securing product approvals in regulated markets.
Dr. Reddy's Laboratories announced that it will release its financial results for the quarter and six months ended September 30, 2026, on Friday, October 23, 2026, following a board meeting. Management is also scheduled to host an earnings call at 19:30 PM IST on the same day to discuss financial and operational performance.
Upcoming earnings disclosures provide critical visibility into revenue growth, margin trends, and management outlook for investors.
The company disclosed that its step-down wholly owned subsidiary, Dr. Reddy's Laboratories, Inc., received a final transcript from the US Internal Revenue Service classifying an amount of $32,350.20 as a penalty. The penalty arose due to a misclassification of the fiscal year reference at the time of tax payment.
The quantifiable penalty is relatively minor and evaluated by management as having no material impact on the financials or operations of the company.
a press release dated October 07, 2026, titled "Intimation of Earnings call".
imposition of penalty to Dr. Reddy s Laboratories, Inc. ( DRL Inc ), a step-down wholly owned subsidiary of the Company.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 13.16% on 30 June 2026. This compares with 13.19% on 31 March 2026, a change of -0.03 percentage points.
The filing reported 40 MF/UTI holders.
What to Watch Next
- Release of Q2FY27 financial results and management commentary on October 23, 2026
- Company response and remediation timeline regarding the USFDA Form 483 observations at the Pydibhimavaram facility
- Delivery volume trends and cash market participation relative to the 20-day average volume
- Progress on commercialization preparation for the Qdenga dengue vaccine partnership
Other Dated Coverage
- Dr. Reddy's Laboratories in Focus After Setting Q2FY27 Earnings Date | 8 October 2026 — 8 October 2026
- Dr. Reddy S Laboratories Share Price Today: Why DRREDDY Is Falling 0.35% | 7 October 2026 — 7 October 2026
- Dr. Reddy's Shares Dip 0.27% Amid Pharma Sector Consolidation | 5 October 2026 — 5 October 2026
More Dr. Reddy S Laboratories news and dated analysis →
Frequently Asked Questions
What is the latest Dr. Reddy S Laboratories company news?
The United States Food and Drug Administration completed a pre-approval inspection at the company's FTO-11 manufacturing facility located in Pydibhimavaram, Andhra Pradesh, between October 5 and October 7, 2026. The inspection concluded with the issuance of a Form 483 containing two observations, which the company stated it will address within the stipulated timeline.
How strong was Dr. Reddy S Laboratories’s trading volume?
1.13 lakh shares traded, 0.05 times the 20-day average daily volume. The price and volume data are dated 13 October 2026 · 09:35 AM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.